Cue Biopharma, Inc. (CUE) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$17.05

From 52W high−57.51%

Volume133109.00

Market cap$116.81M

P/E (TTM)—

P/S (TTM)3.1x

Div yield—

Key dataOct 19, 2026

Open

$17.05

From 52W high

−57.51%

Volume

133109.00

Market cap

$116.81M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.1x

P/E (TTM)

—

RSI (14)

33.3

MomentumView details →

1D Return

−3.77%

YTD Return

+82.53%

SummaryUpdated Jun 1, 2026

Cue Biopharma, Inc. (NASDAQ:CUE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Imagen Biopharma, Inc., the company changed its name to Cue Biopharma in October 2016 and went public in January 2018. The company focuses on developing innovative biologic drugs that selectively modulate the human immune system to treat cancers, chronic infectious diseases, and autoimmune disorders through its proprietary Immuno-STAT platform technology.

Ask drillr about Cue Biopharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.1x

EV/Sales

2.9x

P/S (TTM)

3.1x

P/B (TTM)

50.6x

ProfitabilityView details →

Gross Margin

99.69%

Net Margin

−435.83%

EBITDA Margin

−254.26%

ROE (TTM)

−7104.24%

ROA (TTM)

−534.43%

Asset Turnover

1.22x

GrowthView details →

Revenue YoY

+354.37%

EPS YoY

—

FCF YoY

−77.14%

Revenue CAGR 3Y

+180.46%

EPS CAGR 3Y

+61.11%

EBITDA YoY

—

MomentumView details →

1D Return

−3.77%

YTD Return

+82.53%

1Y Return

−32.09%

RSI (14)

33.3

vs 50D SMA

−38.41%

vs 200D SMA

−19.52%

Capital & dividendView details →

Debt/Equity

3.81x

Current Ratio

1.25x

Quick Ratio

1.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$24.14

EPS Surprise

−1328.40%

Beats (12Q)

10/12

Next Q EPS Est

−$1.76

Avg Surprise (4Q)

−300.09%

Rev Surprise

162.57%

Financials snapshotView financials →

Revenue (TTM)

37.65M

Net Income (TTM)

−164.11M

Op. CF (TTM)

−50.05M

Next earningsNov 11, 2026 →

Latest newsMore news →

Cue Biopharma's stock gave back its premarket gains and was down 3.3%.29d ago

Cue Biopharma reported positive topline results from a clinical trial of CUE-221.30d ago

Similar companies

Spruce Biosciences, Inc.SPRB Anavex Life Sciences Corp.AVXL NRx Pharmaceuticals, Inc.NRXP Outlook Therapeutics, Inc.OTLK TuHURA Biosciences, Inc.HURA Seer, Inc.SEER Find similar companies →

Latest newsMore news →

Cue Biopharma's stock gave back its premarket gains and was down 3.3%.29d ago Cue Biopharma reported positive topline results from a clinical trial of CUE-221.30d ago Cue Biopharma announced the appointment of James M. Ahlers as Chief Financial Officer on August 3, 2026.78d ago